research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
Search
for
Sort by
Research
30 / 1000+ results
research Cutaneous and Mucosal Lichen Planus: A Comprehensive Review of Clinical Subtypes, Risk Factors, Diagnosis, and Prognosis
Lichen Planus is a less common condition affecting skin and mucous membranes, with various types and associated risk factors, challenging to diagnose, significantly impacts life quality, and may have a risk of cancerous changes in oral lesions.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
In Singapore, most skin reactions to drugs were in females and Chinese, often caused by painkillers, antibiotics, and some other drugs, with serious cases linked to genetics.
research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
research Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin
Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
research 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research Topical imiquimod—Be aware of the unexpected
A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research Stimuli-responsive hydrogels for radiation-induced skin injury: from passive barriers to autonomous drug delivery systems
Advanced hydrogels can autonomously deliver drugs to treat radiation skin injuries, but challenges remain for clinical use.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research Tackling Adverse Effects
research Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
research Hypersensitivity to intravenous ondansetron: a case report
Ondansetron can cause serious allergic reactions, so use it carefully.
research A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
ZD1839 can cause skin issues like acne and hair changes.
research β-sitosterol in Yijing Hugui decoction prevents cyclophosphamide-induced premature ovarian insufficiency via the AKT1/Nrf2 pathway
research C-2-3 GND-VIAを用いたX帯SiGe-MMIC増幅器(C-2. マイクロ波A(能動デバイス), エレクトロニクス1)
Cancer prevention has advanced significantly, with some strategies proving successful.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research Using risk analysis to guide changes to compounding formulae
Risk analysis is important for safely adjusting pharmaceutical formulas while maintaining their quality and effectiveness.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research Does Inhibition of Aldose Reductase Contribute to the Anti-Inflammatory Action of Setipiprant?
Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
research RAGE and Its Ligands in Melanoma
RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.
research Proposal Statement
Stronger regulations and protections are needed for digital platforms to ensure safety and fairness in health, education, and labor.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Abstract SS02-02: Chemoprevention: Poised for Success
Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
research Risk of finasteride-related suicidal ideation
research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.